News

New modelling shows annual multi-cancer early detection (MCED) tests could cut late-stage diagnoses by 49%. RMDM Group’s PanTum Detect goes further—identifying both early-stage cancers and precancerous changes with high accuracy. With a positive predictive value of 66.47%, it offers a powerful, non-invasive tool to fill gaps in current screening and shift oncology towards true prevention.

While sugar is often seen as a cancer culprit, new research shows it can also be a powerful tool in diagnosis, treatment, and prevention. From the tumour-fuelling role of glucose to the therapeutic potential of functional sugars like mannose, this article explores how understanding sugar metabolism—especially through the TKTL1 gene and the Dr Coy Principle—could transform cancer care.

A recent study published in JAMA Otolaryngology has uncovered a concerning link between the consumption of sugar-sweetened beverages (SSBs) and an increased risk of oral cavity cancer in women, including both smokers and non-smokers. The findings show that women who regularly consumed sugary drinks were found to have a significantly higher risk of developing oral cavity cancers compared to those who consumed them less frequently.

The AI-powered prostate cancer test developed by EDX Medical Group represents a major advancement in early detection. By analysing over 100 biological markers in blood and urine samples, it offers a more accurate assessment of prostate cancer risk than traditional methods like PSA testing, highlighting the critical role of early detection in improving patient outcomes.

We are witnessing a crucial moment for the NHS as it promises to reduce waiting lists and deliver timely care. This commitment resonates with patients and healthcare professionals. However, while the intentions behind these proposals are laudable, critical questions remain regarding their feasibility, workforce capacity, and long-term sustainability by the NHS.

Olympic cyclist Sir Chris Hoy is advocating for improved prostate cancer tests for younger men following his terminal diagnosis in September 2023. His recent interview with the BBC reveals the limitations of the NHS’s current protocol for prostate cancer testing.

In a recent press release, the UK government outlined an initiative to boost tech deals aimed at further innovating cancer diagnosis in the country.
This plan follows the Darzi review, which highlighted the critical state of the NHS, particularly the urgent need to improve cancer survival rates.

In the House of Commons, Health Secretary Wes Streeting introduced a “national mission” to tackle key health challenges. Presenting the Darzi report, commissioned by the Labour government, he outlined the NHS’s ongoing struggles in the post-pandemic era, including missed targets in cancer care, A&E services, and hospital treatment.

​Last month, the UK National Screening Committee (UK NSC) shared their updated view on Multi-Cancer Detection (MCD) tests. They highlighted the potential and the immediate need for a multi-cancer detection solution in the UK. They are working to outline a roadmap for...